Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

Thomas Walter Department of Gastroenterology and Digestive Oncology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France; University of Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France; INSERM, U865, Faculté Laënnec, Lyon, FranceCorrespondence[email protected]

Jean-Yves Scoazec University of Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France; Department of Pathology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France; INSERM, U865, Faculté Laënnec, Lyon, France

Christophe Couderc University of Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France; INSERM, U865, Faculté Laënnec, Lyon, France

Julien Forestier Department of Gastroenterology and Digestive Oncology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France

Colette Roche University of Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France; INSERM, U865, Faculté Laënnec, Lyon, France

Jean-Alain Chayvialle Department of Gastroenterology and Digestive Oncology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France; University of Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France; INSERM, U865, Faculté Laënnec, Lyon, France

Catherine Lombard-Bohas Department of Gastroenterology and Digestive Oncology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France

show all

"Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?." Acta Oncologica, 50(5), pp. 731–732

Declaration of interest: This work was supported by no funding. The authors have declared no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

Information for

Open access

Opportunities

Help and information

Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature